India, July 24 -- Biosergen AB (publ) (8N1.F), Thursday announced the appointment of Mark Beveridge as its new Chief Financial Officer, succeeding Niels Laursen, who will remain with the company to ensure a smooth transition.
Recently, Beveridge serves as Vice President Finance at Moberg Pharma. He plans to continue in this role alongside his new responsibilities at Biosergen.
Tine Olesen, CEO of Biosergen, commented, "Mark's experience will be highly valuable as we continue our mission to develop life-saving antifungal therapies for patients with an unmet medical need."
Currently, Biosergen's stock is moving down 5.86 percent, to 0.0450 euros on the Frankfurt.
For comments and feedback contact: editorial@rttnews.com
Published by HT Di...